《睡眠專業人士雜誌》
星期六, 七月 25, 2026
Apnimed, Inc., announced that it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (“HCRx”). The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed’s lead product candidate, AD109, if approved by the […]
即使您並非習慣訂立新年決心的那類人，新年的到來自然會讓人反思：去年哪些事情做得不錯、哪些需要改變，以及該拋下什麼。秉持著這種展望未來的精神，《SleepWorld》雜誌進行了首屆讀者科技問卷調查 […]
身為一名睡眠專科醫師，我所面臨最令人沮喪的現實之一，並非缺乏診斷工具，而是患者在取得這些工具時所面臨的障礙。阻塞性睡眠呼吸中止症（OSA）是一種常見且嚴重的疾病，卻普遍被漏診。據估計，美國有超過 3,000 萬名成年人患有 […]
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
On 三月 25, United States District Court Judge Rebecca L. Pennell sentenced Dr. Eric Edward Haeger, age 57, of Brewster, Washington, to one year and a day in federal prison followed by a one-year term of supervised release after Haeger pleaded guilty to adulterating and misbranding medical devices with the […]
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
Eli Lilly and Company and Centessa Pharmaceuticals plc, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to […]
Narcolepsy is a chronic condition in which someone feels excessively sleepy, occasionally falling asleep without warning. This can have a major impact on their daily lives, affecting not only their education and employment, but also their ability to drive, their relationships, and their emotional health. “It’s quite striking when you’re […]
AI software designed to help diagnose sleep apnea in children has achieved high accuracy in an NHS trial, with the findings independently reviewed by clinical specialists. Glasgow company Seluna tested its autoscoring and sleep staging software on 500 retrospective sleep studies from NHS Greater Glasgow and Clyde’s Royal Hospital for […]
LivaNova PLC 宣布，美國食品藥物管理局（FDA）已核准 aura6000™ 系統用於治療中度至重度阻塞性睡眠呼吸中止症（OSA）的成人患者，並授予上市前核准（PMA）。 該系統採用近端舌下神經刺激（p-HGNS）——一種獨特的神經刺激療法——來治療患有 […] 的 OSA 患者。
